Safety of RU-58841: I talked to the Pharma Company that researched it, Human Clinical Trials, and Potential Reasons for Discontinuation
    Research/Science 10/12/2023

    The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.
    View this post in the Community β†’

    Similar Community Posts Join

    6 / 1000+ results

    Related Research

    6 / 577 results
      Therapeutic Strategies for Treating Hair Loss

      research Therapeutic Strategies for Treating Hair Loss

      42 citations, March 2006 in “Drug Discovery Today: Therapeutic Strategies”
      The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.
      Nanotechnology in Dermatology

      research Nanotechnology in Dermatology

      60 citations, January 2014 in “Anais Brasileiros De Dermatologia”
      Nanotechnology in dermatology shows promise for better drug delivery and treatment effectiveness but requires more safety research.
      Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      research Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      November 2020 in “Elsevier eBooks”
      Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.